Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Potential of Cannabidiol for the Treatment of Viral Hepatitis.

Lowe HI, Toyang NJ, McLaughlin W.

Pharmacognosy Res. 2017 Jan-Mar;9(1):116-118. doi: 10.4103/0974-8490.199780.

2.

Transient Cannabinoid Receptor 2 Blockade during Immunization Heightens Intensity and Breadth of Antigen-specific Antibody Responses in Young and Aged mice.

Dotsey E, Ushach I, Pone E, Nakajima R, Jasinskas A, Argueta DA, Dillon A, DiPatrizio N, Davies H, Zlotnik A, Crompton PD, Felgner PL.

Sci Rep. 2017 Feb 17;7:42584. doi: 10.1038/srep42584.

3.

Synthetic Cannabinoid-Induced Immunosuppression Augments Cerebellar Dysfunction in Tetanus-Toxin Treated Mice.

Yun J, Gu SM, Lee TH, Song YJ, Seong S, Kim YH, Cha HJ, Han KM, Shin J, Oh H, Jung K, Ahn C, Park HK, Kim HS.

Biomol Ther (Seoul). 2017 May 1;25(3):266-271. doi: 10.4062/biomolther.2016.116.

4.

Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation.

McCoy KL.

Mediators Inflamm. 2016;2016:5831315. doi: 10.1155/2016/5831315. Epub 2016 Aug 11. Review.

5.

High on Cannabis and Calcineurin Inhibitors: A Word of Warning in an Era of Legalized Marijuana.

Hauser N, Sahai T, Richards R, Roberts T.

Case Rep Transplant. 2016;2016:4028492. doi: 10.1155/2016/4028492. Epub 2016 Aug 9.

6.

Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB.

Boileau I, Mansouri E, Williams B, Le Foll B, Rusjan P, Mizrahi R, Tyndale RF, Huestis MA, Payer DE, Wilson AA, Houle S, Kish SJ, Tong J.

Biol Psychiatry. 2016 Nov 1;80(9):691-701. doi: 10.1016/j.biopsych.2016.04.012. Epub 2016 Apr 25.

PMID:
27345297
7.

RNA-seq Analysis of δ9-Tetrahydrocannabinol-treated T Cells Reveals Altered Gene Expression Profiles That Regulate Immune Response and Cell Proliferation.

Yang X, Bam M, Nagarkatti PS, Nagarkatti M.

J Biol Chem. 2016 Jul 22;291(30):15460-72. doi: 10.1074/jbc.M116.719179. Epub 2016 Jun 6.

PMID:
27268054
8.

A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.

Giacoppo S, Galuppo M, Pollastro F, Grassi G, Bramanti P, Mazzon E.

Daru. 2015 Oct 21;23:48. doi: 10.1186/s40199-015-0131-8.

9.

Effects of Cannabinoids on T-cell Function and Resistance to Infection.

Eisenstein TK, Meissler JJ.

J Neuroimmune Pharmacol. 2015 Jun;10(2):204-16. doi: 10.1007/s11481-015-9603-3. Epub 2015 Apr 16. Review.

10.

Effects of pro-inflammatory cytokines on cannabinoid CB1 and CB2 receptors in immune cells.

Jean-Gilles L, Braitch M, Latif ML, Aram J, Fahey AJ, Edwards LJ, Robins RA, Tanasescu R, Tighe PJ, Gran B, Showe LC, Alexander SP, Chapman V, Kendall DA, Constantinescu CS.

Acta Physiol (Oxf). 2015 May;214(1):63-74. doi: 10.1111/apha.12474. Epub 2015 Mar 10.

11.

Epigenetic Regulation of Immunological Alterations Following Prenatal Exposure to Marijuana Cannabinoids and its Long Term Consequences in Offspring.

Zumbrun EE, Sido JM, Nagarkatti PS, Nagarkatti M.

J Neuroimmune Pharmacol. 2015 Jun;10(2):245-54. doi: 10.1007/s11481-015-9586-0. Epub 2015 Jan 25. Review.

12.

Exposure to Δ9-Tetrahydrocannabinol Impairs the Differentiation of Human Monocyte-derived Dendritic Cells and their Capacity for T cell Activation.

Roth MD, Castaneda JT, Kiertscher SM.

J Neuroimmune Pharmacol. 2015 Jun;10(2):333-43. doi: 10.1007/s11481-015-9587-z. Epub 2015 Jan 23.

13.

Polyunsaturated Fatty Acid-derived lipid mediators and T cell function.

Nicolaou A, Mauro C, Urquhart P, Marelli-Berg F.

Front Immunol. 2014 Feb 25;5:75. doi: 10.3389/fimmu.2014.00075. eCollection 2014. Review.

14.

Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS.

Kong W, Li H, Tuma RF, Ganea D.

Cell Immunol. 2014 Jan;287(1):1-17. doi: 10.1016/j.cellimm.2013.11.002. Epub 2013 Nov 14.

15.

Suppression by Δ(9)-tetrahydrocannabinol of the primary immunoglobulin M response by human peripheral blood B cells is associated with impaired STAT3 activation.

Ngaotepprutaram T, Kaplan BL, Carney S, Crawford R, Kaminski NE.

Toxicology. 2013 Aug 9;310:84-91. doi: 10.1016/j.tox.2013.05.009. Epub 2013 May 29.

16.

Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells.

Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Gao F, Coppola G, Geschwind D, Vogel Z.

PLoS One. 2013 Apr 24;8(4):e61462. doi: 10.1371/journal.pone.0061462. Print 2013.

17.

Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.

Rom S, Persidsky Y.

J Neuroimmune Pharmacol. 2013 Jun;8(3):608-20. doi: 10.1007/s11481-013-9445-9. Epub 2013 Mar 8. Review.

18.

The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Cooper ME, Regnell SE.

Br J Clin Pharmacol. 2014 Jan;77(1):21-30. doi: 10.1111/bcp.12102. Review.

19.

Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia.

Matarese G, La Rocca C, Moon HS, Huh JY, Brinkoetter MT, Chou S, Perna F, Greco D, Kilim HP, Gao C, Arampatzi K, Wang Z, Mantzoros CS.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):E818-27. doi: 10.1073/pnas.1214554110. Epub 2013 Feb 4.

20.

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.

Leussink VI, Husseini L, Warnke C, Broussalis E, Hartung HP, Kieseier BC.

Ther Adv Neurol Disord. 2012 Sep;5(5):255-66. doi: 10.1177/1756285612453972.

Supplemental Content

Support Center